Brent Zettl, Präsident und CEO CanniMed: “We fully expect that both CanniMed and Aurora shareholders will be surprised by these actions and realize the inconsistency between what Aurora’s board and management says and what they do. The most logical inference from what they have done is that they believe Aurora cannot and will not remain at its currently inflated valuation. Shareholders should ask themselves if they can trust an Aurora management team who are publicly talking up the stock and trying to convince CanniMed shareholders to tender to their opportunistic and coercive bid, while at the same time selling and taking millions in dollars for themselves. We ask CanniMed shareholders to compare these action to their words and draw their own conclusions.”